Survivin-Directed Cancer Vaccine Therapy

摘要

The invention relates to a therapeutically effective truncated survivin and its therapeutic use as vaccine in a liposomal preparation, wherein the survivin fragment is preferably gluconoylated, and said liposomal preparation elicits in-vivo anti-tumor activity. The invention is directed, in more detail, to a cancer vaccine comprising a fragment of human survivin that is specifically effective in conjunction with an lipid adjuvant. The invention relates in more detail to a liposomal vaccine delivery system comprising an active truncated survivin molecule as tumor antigen and a chiral cationic lipid, for example R-DOTAP acting as adjuvant, which is part of the liposome preparation, wherein the liposomal drug delivery system is optimized with regard to its lipid and adjuvant components, physical or physicochemical parameters, and the final therapeutic efficacy of the released truncated survivin molecules. The invention is finally related to a method of increasing CD4+/CD8+ T-cell responses in-vivo, thus resulting in an increased anti-tumor activity by providing a liposome preparation comprising said truncated preferably gluconoylated survivin.

主权项

1. A C-terminally truncated survivin consisting of the first 118-133 N-terminal amino acids of full-length human survivin represented by SEQ ID NO: 1, or a sequence having a homology to said truncated survivin of >90%, wherein the truncated survivin is gluconylated at one or more positions having free amino residues.